OnKure Therapeutics, Inc.
$ 2.80
-1.75%
26 Dec - close price
- Market Cap 37,935,000 USD
- Current Price $ 2.80
- High / Low $ 2.91 / 2.70
- Stock P/E N/A
- Book Value 4.90
- EPS -4.68
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.96 %
- ROE -2.07 %
- 52 Week High 9.40
- 52 Week Low 1.70
About
OnKure Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in Boulder, Colorado, specializing in precision oncology to address significant unmet needs in cancer therapies. The company utilizes advanced drug discovery platforms to develop targeted therapies that embody its dedication to personalized medicine. With a strong pipeline of promising therapeutic candidates, OnKure aims to enhance patient outcomes and redefine standards in oncology treatment. Its strategic commitment to transforming cancer care positions OnKure as a key player in the biopharmaceutical landscape.
Analyst Target Price
$27.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-13 | 2025-05-05 | 2025-03-11 | 2024-11-06 | 2024-08-13 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-27 |
| Reported EPS | -1.09 | -1.14 | -1.1863 | -1.37 | -0.86 | -1.6041 | -2.5212 | -7.0477 | -5.678 | -6.4639 | -6.034 | -5.5368 |
| Estimated EPS | -1.198 | -1.248 | -1.38 | -0.87 | -0.9 | None | None | None | None | None | None | None |
| Surprise | 0.108 | 0.108 | 0.1937 | -0.5 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | 9.015% | 8.6538% | 14.0362% | -57.4713% | 4.4444% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKUR
2024-05-15 15:09:12
Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals on intellectual property matters concerning its definitive merger agreement with OnKure, Inc. This all-stock transaction will combine the two biopharmaceutical companies with a focus on advancing OnKure’s oncology pipeline targeting PI3Kα, including its lead program OKI-219. The combined entity will operate as OnKure Therapeutics, Inc., trading under the ticker symbol "OKUR" on the Nasdaq Global Market, with the merger anticipated to close in 2024.
